Cite

    Trujillo, J. et al. (2018). Low incidence of gastrointestinal adverse events over time with a fixed‐ratio combination of insulin glargine and lixisenatide versus lixisenatide alone. Diabetes, obesity & metabolism. 20 (11), pp. 2690-2694. [Online].